Literature DB >> 15945019

High turbulence liquid chromatography online extraction and tandem mass spectrometry for the simultaneous determination of suberoylanilide hydroxamic acid and its two metabolites in human serum.

Lihong Du1, Donald G Musson, Amy Qiu Wang.   

Abstract

A reliable and sensitive method incorporating high turbulence liquid chromatography (HTLC) online extraction with tandem mass spectrometry (MS/MS), for simultaneous determination of suberoylanilide hydroxamic acid (SAHA) and its two metabolites, SAHA-glucuronide (M1) and 4-anilino-4-oxobutanoic acid (M2), in human serum, has been developed to support clinical studies. The HTLC technology significantly reduces the time required for sample clean-up since sample extraction and analysis are performed online. Clinical samples, internal standards (IS) and buffer are transferred into 96-well plates using a robotic liquid handling system. A 20 microL aliquot of prepared sample is directly injected into the HTLC/LC-MS/MS system where the matrix is rapidly washed away to waste and the analytes are retained on the narrow-bore extraction column (0.5 x 50 mm), using an aqueous mobile phase at 1.5 mL/min. Analytes are then eluted from the extraction column and transferred to the analytical column using a gradient mobile phase prior to detection by MS/MS. Interference with determination of SAHA from in-source dissociation of M1 is eliminated by the chromatographic separation. The resolution of SAHA and M1 did not change for more than 1500 serum sample injections by applying an acid wash (15% acetic acid) on the extraction column. The linear calibration ranges for SAHA, M1, and M2 are 2-500, 5-2000, and 10-2000 ng/mL, respectively. Assay intraday validation was conducted using five calibration curves prepared in five lots of human control serum. The precision expressed as relative standard deviation (RSD) is less than 6.8% and accuracy is 94.6-102.9% of nominal values for all three analytes. Assay specificity, freeze/thaw stability, storage stability, and matrix effects were also assessed. Copyright (c) 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15945019     DOI: 10.1002/rcm.1984

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  10 in total

Review 1.  Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Authors:  Jacqueline Ramírez; Mark J Ratain; Federico Innocenti
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

2.  Vorinostat with sustained exposure and high solubility in poly(ethylene glycol)-b-poly(DL-lactic acid) micelle nanocarriers: characterization and effects on pharmacokinetics in rat serum and urine.

Authors:  Elham A Mohamed; Yunqi Zhao; Mahasen M Meshali; Connie M Remsberg; Thanaa M Borg; Abdel Monem M Foda; Jody K Takemoto; Casey L Sayre; Stephanie E Martinez; Neal M Davies; M Laird Forrest
Journal:  J Pharm Sci       Date:  2012-07-17       Impact factor: 3.534

3.  HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat.

Authors:  Nancy M Archin; Rosalie Bateson; Manoj K Tripathy; Amanda M Crooks; Kuo-Hsiung Yang; Noelle P Dahl; Mary F Kearney; Elizabeth M Anderson; John M Coffin; Matthew C Strain; Douglas D Richman; Kevin R Robertson; Angela D Kashuba; Ronald J Bosch; Daria J Hazuda; Joann D Kuruc; Joseph J Eron; David M Margolis
Journal:  J Infect Dis       Date:  2014-03-11       Impact factor: 5.226

4.  Elevated Plasma Viral Loads in Romidepsin-Treated Simian Immunodeficiency Virus-Infected Rhesus Macaques on Suppressive Combination Antiretroviral Therapy.

Authors:  Gregory Q Del Prete; Kelli Oswald; Abigail Lara; Rebecca Shoemaker; Jeremy Smedley; Rhonda Macallister; Vicky Coalter; Adam Wiles; Rodney Wiles; Yuan Li; Randy Fast; Rebecca Kiser; Bing Lu; Jim Zheng; W Gregory Alvord; Charles M Trubey; Michael Piatak; Claire Deleage; Brandon F Keele; Jacob D Estes; Joseph Hesselgesser; Romas Geleziunas; Jeffrey D Lifson
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

5.  Mass spectrometry imaging in zebrafish larvae for assessing drug safety and metabolism.

Authors:  Mariana Asslan; Nidia Lauzon; Maja Beus; Dusica Maysinger; Simon Rousseau
Journal:  Anal Bioanal Chem       Date:  2021-06-26       Impact factor: 4.142

6.  Simultaneous determination of cyclophosphamide and carboxyethylphosphoramide mustard in human plasma using online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS/MS).

Authors:  Feng Bai; Charles H Fraga; Michael Tagen; Paula Schaiquevich; Nikolaus Hagedorn; Clinton F Stewart
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-04-24       Impact factor: 3.205

7.  Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype.

Authors:  Renee M Balliet; Gang Chen; Carla J Gallagher; Ryan W Dellinger; Dongxiao Sun; Philip Lazarus
Journal:  Cancer Res       Date:  2009-03-24       Impact factor: 12.701

8.  Determination of Flavonoids and Resveratrol in Wine by Turbulent-Flow Chromatography-LC-MS.

Authors:  Michele Antoniuk Presta; Ben Bruyneel; Renato Zanella; Jeroen Kool; Johannes G Krabbe; Henk Lingeman
Journal:  Chromatographia       Date:  2009-05-26       Impact factor: 2.044

9.  Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients.

Authors:  Ling-Zhi Wang; Jacqueline Ramírez; Winnie Yeo; Mei-Yi Michelle Chan; Win-Lwin Thuya; Jie-Ying Amelia Lau; Seow-Ching Wan; Andrea Li-Ann Wong; Ying-Kiat Zee; Robert Lim; Soo-Chin Lee; Paul C Ho; How-Sung Lee; Anthony Chan; Sherry Ansher; Mark J Ratain; Boon-Cher Goh
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

10.  Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.

Authors:  N M Archin; A L Liberty; A D Kashuba; S K Choudhary; J D Kuruc; A M Crooks; D C Parker; E M Anderson; M F Kearney; M C Strain; D D Richman; M G Hudgens; R J Bosch; J M Coffin; J J Eron; D J Hazuda; D M Margolis
Journal:  Nature       Date:  2012-07-25       Impact factor: 49.962

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.